-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 --
-- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 --
Comments